HDAC Up-Regulation in Early Colon Field Carcinogenesis Is Involved in Cell Tumorigenicity through Regulation of Chromatin Structure

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Stypula Cyrus, Yolanda ^a   Damania, Dhwanil ^a   Kunte, Dhananjay P ^b   Cruz, Mart Dela ^c   Subramanian, Hariharan ^a   Roy, Hemant K ^c   Backman, Vadim ^a  

^a Northwestern University   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; NUCLEASE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL STRAIN HT29; CELL VIABILITY; CELLULAR DISTRIBUTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CHROMOSOME REARRANGEMENT; COLON CANCER; COLON CARCINOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; NONHUMAN; PARTIAL WAVE SPECTROSCOPY; PROTEIN EXPRESSION; RAT; SPECTROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION;

ANIMALS; CARCINOGENESIS; CELL SURVIVAL; CHROMATIN; COLORECTAL NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HT29 CELLS; HUMANS; INTESTINAL MUCOSA; RATS; RATS, INBRED F344; SPECTRUM ANALYSIS; UP-REGULATION; VALPROIC ACID;

RATTUS;

EID: 84878401588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064600     Document Type: Article

References (51)

1. Sawan C, Herceg Z, (2010) Histone modifications and cancer. Adv Genet 70: 57-85.
2. Lao VV, Grady WM (2011) Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol.
3. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, et al. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237.
4. Kinzler KW, Vogelstein B, (1996) Lessons from hereditary colorectal cancer. Cell 87: 159-170.
5. Fang DC, Luo YH, Yang SM, Li XA, Ling XL, et al. (2002) Mutation analysis of APC gene in gastric cancer with microsatellite instability. World J Gastroenterol 8: 787-791.
6. Chai H, Brown RE, (2009) Field effect in cancer-an update. Ann Clin Lab Sci 39: 331-337.
7. Venkatachalam R, Ligtenberg MJ, Hoogerbrugge N, de Bruijn DR, Kuiper RP, et al. (2010) The epigenetics of (hereditary) colorectal cancer. Cancer Genet Cytogenet 203: 1-6.
8. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, et al. (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97: 1330-1338.
9. Nosho K, Kure S, Irahara N, Shima K, Baba Y, et al. (2009) A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 137: 1609-1620 e1601-1603.
10. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH, (2003) A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Research 63: 1727-1730.
11. Backman V, Roy HK, (2011) Light-scattering technologies for field carcinogenesis detection: a modality for endoscopic prescreening. Gastroenterology 140: 35-41.
12. Pradhan P, Damania D, Joshi HM, Turzhitsky V, Subramanian H, et al. (2011) Quantification of nanoscale density fluctuations using electron microscopy: Light-localization properties of biological cells. Appl Phys Lett 97: 243704.
13. Subramanian H, Pradhan P, Liu Y, Capoglu IR, Rogers JD, et al. (2009) Partial-wave microscopic spectroscopy detects subwavelength refractive index fluctuations: an application to cancer diagnosis. Opt Lett 34: 518-520.
14. Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, et al. (2009) Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res 69: 5357-5363.
15. Marks PA, Richon VM, Breslow R, Rifkind RA, (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483.
16. Minucci S, Pelicci PG, (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
17. Kawai H, Li H, Avraham S, Jiang S, Avraham HK, (2003) Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107: 353-358.
18. Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, et al. (2009) Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci 54: 2109-2117.
19. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, et al. (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18: 769-774.
20. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, et al. (2009) Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 15: 3163-3171.
21. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, et al. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463.
22. Marks PA, Richon VM, Rifkind RA, (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216.
23. Ropero S, Esteller M, (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19-25.
24. Taddei A, Roche D, Bickmore WA, Almouzni G, (2005) The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6: 520-524.
25. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
26. Kunte DP, Wali RK, Koetsier JL, Hart J, Kostjukova MN, et al. (2005) Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. FEBS Lett 579: 3497-3502.
27. Damania D, Subramanian H, Tiwari AK, Stypula Y, Kunte D, et al. (2010) Role of cytoskeleton in controlling the disorder strength of cellular nanoscale architecture. Biophys J 99: 989-996.
28. Kunte DP, Wali RK, Koetsier JL, Roy HK, (2008) Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase. Mol Cancer Ther 7: 1797-1806.
29. Subramanian H, Pradhan P, Liu Y, Capoglu IR, Li X, et al. (2008) Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells. Proc Natl Acad Sci U S A 105: 20118-20123.
30. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, et al. (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22: 3411-3420.
31. Barer R, Tkaczyk S, (1954) Refractive index of concentrated protein solutions. Nature 173: 821-822.
32. Davies HG, Wilkins MHF, Chayen J, Lacour LF (1954) The Use of the Interference Microscope to Determine Dry Mass in Living Cells and as a Quantitative Cytochemical Method. Quarterly Journal of Microscopical Science 95: 271-&.
33. Backman V, Kim JS, Pradhan P, Szleifer I (2011) The influence of chromosome density variations on the increase in nuclear disorder strength in carcinogenesis. Physical Biology 8.
34. Zaret K (2005) Micrococcal nuclease analysis of chromatin structure. Curr Protoc Mol Biol Chapter 21: Unit 21 21.
35. Kramer OH, Gottlicher M, Heinzel T, (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12: 294-300.
36. Wali RK, Roy HK, Kim YL, Liu Y, Koetsier JL, et al. (2005) Increased microvascular blood content is an early event in colon carcinogenesis. Gut 54: 654-660.
37. Banerjee A, Quirke P, (1998) Experimental models of colorectal cancer. Dis Colon Rectum 41: 490-505.
38. Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, et al. (2006) Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311: 844-847.
39. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
40. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, et al. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76.
41. Gorisch SM, Wachsmuth M, Toth KF, Lichter P, Rippe K, (2005) Histone acetylation increases chromatin accessibility. J Cell Sci 118: 5825-5834.
42. Van Lint C, Emiliani S, Verdin E, (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253.
43. Kim JS, Pradhan P, Backman V, Szleifer I, (2011) The influence of chromosome density variations on the increase in nuclear disorder strength in carcinogenesis. Phys Biol 8: 015004.
44. Egger G, Liang G, Aparicio A, Jones PA, (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
45. Misteli T, (2010) Higher-order genome organization in human disease. Cold Spring Harb Perspect Biol 2: a000794.
46. Orr HT, Zoghbi HY, (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30: 575-621.
47. Alberts DS, Einspahr JG, Krouse RS, Prasad A, Ranger-Moore J, et al. (2007) Karyometry of the colonic mucosa. Cancer Epidemiol Biomarkers Prev 16: 2704-2716.
48. Richon VM, Sandhoff TW, Rifkind RA, Marks PA, (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97: 10014-10019.
49. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, et al. (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 102: 16090-16095.
50. Roy HK, Subramanian H, Damania D, Hensing TA, Rom WN, et al. (2010) Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res 70: 7748-7754.
51. Michor F, Liphardt J, Ferrari M, Widom J, (2011) What does physics have to do with cancer? Nat Rev Cancer 11: 657-670.